In this article, we will be taking a look at the 10 High Growth Pharma Stocks That Are Profitable in 2025.

Emily Field, the head of Barclays’ European pharmaceutical research, spoke on CNBC on July 14 about which pharmaceutical companies will be most affected by 30% US tariffs on EU imports. Field believes that because of their complex and secret supply lines, it is difficult to pinpoint the businesses that are most affected. “There haven’t been any country-specific requests for carve-outs,” Field said in reference to the European pharmaceutical companies urging the US administration for similar carve-outs, particularly in light of President Trump’s proposal to impose tariffs of up to 200% on pharmaceutical imports. She did note, though, that a number of European businesses have announced significant plans to invest in US manufacturing.

She added that the administration is working with these companies on the nation’s preferred drug price policy. According to Field, these initiatives are related and seek a mutually advantageous agreement between the government and the sector, which may include a mix of medication pricing regulations and tariffs. She said that the pharmaceutical industry is not subject to the present country-specific tariffs, which she said could be one of the reasons why the European healthcare index was doing better that day than the overall European index.

She clarified that the Commerce Department is conducting a Section 232 inquiry and that the findings, which will establish sector-specific tariffs, should be available by the end of the month. Before the President announced a possible 200% tariff, most people had 25% expectations. Nonetheless, the industry has always argued that tariffs would harm patients by possibly causing drug shortages.

With this in mind, let’s take a look at the high growth pharma stocks that are profitable in 2025.  

Our Methodology 

We filtered stocks using a screener, applying criteria of five-year revenue growth exceeding 25% and trailing twelve-month (TTM) net income above $500 million. From the resulting list, we selected the stocks with the highest number of hedge fund holders as of Q2 2025, as tracked by the Insider Monkey database, and ranked them in ascending order.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 10 high growth pharma stocks that are profitable in 2025.

10. Biogen Inc. (NASDAQ:BIIB)

Number of Hedge Fund Holders: 55

Biogen Inc. (NASDAQ:BIIB), founded in 1978 and headquartered in Cambridge, Massachusetts, continues to strengthen its leadership in neurological disorders, with a particular focus on Alzheimer’s disease. It stands tenth on our list among the high growth stocks. In April 2025, the European Commission approved lecanemab (Leqembi), developed with Eisai, marking Austria and Germany as its first EU markets. The therapy is now approved in 48 countries, with a U.S. FDA decision on a subcutaneous autoinjector formulation expected by August 31, 2025. Large Phase 3 trials, including AHEAD 3-45 for individuals at risk and Tau NexGen for inherited Alzheimer’s, highlight the company’s push into preclinical and familial forms of the disease.

To support this growing pipeline, Biogen Inc. (NASDAQ:BIIB) is investing $2 billion to expand its Research Triangle Park (RTP) operations in North Carolina. The new facility, set to be operational by late 2025, will feature advanced automation, expanded antisense oligonucleotide capabilities, and multi-platform fill-finish operations. With more than $10 billion invested in RTP since 1995, the business has cemented itself as a cornerstone of the state’s biopharma industry while ensuring a resilient supply for future launches.

Beyond Alzheimer’s, Biogen Inc. (NASDAQ:BIIB) is advancing therapies across multiple high-need areas. Zorevunersen, an antisense drug for Dravet syndrome, is expected to deliver pivotal Phase 3 results by 2027. Salanersen, a potential breakthrough for spinal muscular atrophy, is moving toward Phase 3 trials following positive early data. Felzartamab, an anti-CD38 therapy, is in late-stage studies for rare kidney diseases, while dapirolizumab pegol has shown encouraging results in lupus by improving fatigue and disease activity.

9. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 62

Amgen Inc. (NASDAQ:AMGN), the California-based biotech giant, continues to strengthen its leadership in cardiovascular, oncology, respiratory, and rare diseases while expanding into new therapeutic frontiers.

In Q2 2025, the company posted a 9% year-over-year revenue increase, fueled by double-digit growth across 15 core products. Investment in R&D climbed 18%, with the company prioritizing high-impact areas like obesity, cardiovascular disease, and oncology. A $900 million manufacturing expansion in Ohio will support future supply and create hundreds of new jobs, underscoring the business’s commitment to scaling its pipeline.

The spotlight remains on MariTide, Amgen Inc. (NASDAQ:AMGN)’s experimental obesity drug designed to target both GLP-1 and GIP receptors for potentially superior weight-loss outcomes. Key Phase 2 trial results are expected in late 2025, including studies in both obesity and type 2 diabetes. Early data suggests patients could achieve weight loss of up to 20%, positioning MariTide as a potential disruptor in a market projected to exceed $150 billion globally.

Regulatory and clinical momentum also continues across Amgen Inc. (NASDAQ:AMGN)’s portfolio. In August 2025, Repatha gained expanded FDA approval for adults at elevated risk of major cardiovascular events, while Tezspire posted 46% sales growth year-over-year as adoption in severe asthma accelerates. Meanwhile, biosimilars revenue jumped 40%, strengthening margins and expanding access to affordable therapies.